Paraproteinemias: Clinical Trials

4,280 trials for Paraproteinemias, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

1970 completed, 598 recruiting, 566 terminated, 390 unknown. 1882 Phase 2, 1389 Phase 1, 418 Phase 3, 375 Not applicable, 101 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	1882	Completed 900, Terminated 291, Recruiting 206, Active not recruiting 175, Unknown 148, Withdrawn 100, Not yet recruiting 53, Suspended 6, Enrolling by invitation 3
Phase 1	1389	Completed 654, Terminated 246, Recruiting 171, Unknown 123, Active not recruiting 93, Withdrawn 51, Not yet recruiting 43, Suspended 7, Enrolling by invitation 1
Phase 3	418	Completed 212, Active not recruiting 54, Recruiting 52, Unknown 42, Terminated 32, Not yet recruiting 19, Withdrawn 6, Suspended 1
Not applicable	375	Completed 152, Recruiting 82, Terminated 45, Unknown 37, Not yet recruiting 26, Active not recruiting 18, Withdrawn 11, Suspended 3, Enrolling by invitation 1
Early Phase 1	101	Recruiting 29, Unknown 25, Not yet recruiting 14, Completed 13, Active not recruiting 6, Terminated 6, Withdrawn 6, Suspended 2
Phase 4	62	Completed 26, Recruiting 11, Unknown 9, Not yet recruiting 6, Active not recruiting 4, Withdrawn 4, Terminated 2

Follow Paraproteinemias: new trials by email Literature Review of Paraproteinemias trials Research Report on Paraproteinemias

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 2	Not yet recruiting	Excyte Biopharma Ltd	64	2027-12-01	2026-11-06
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-30	2026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma	Phase 1	Withdrawn	Fred Hutchinson Cancer Center		2027-06-01	2026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	National Cancer Institute (NCI)	80	2027-05-22	2026-11-04
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	162	2027-04-12	2026-10-16
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)	Phase 2	Not yet recruiting	Zealand University Hospital	150	2027-03-01	2026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)	Phase 2	Not yet recruiting	University of Arkansas	50	2027-03-01	2026-09-02
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma	Phase 4	Not yet recruiting	Anne Louise Tølbøll Sørensen	400	2027-03-01	2026-03-16
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma	Phase 1	Not yet recruiting	University of Chicago	32	2027-02-23	2026-10-22
Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia	Phase 2	Not yet recruiting	Massachusetts General Hospital	24	2027-02-19	2026-09-01
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma	Phase 3	Not yet recruiting	Kite, A Gilead Company	750	2027-02-01	2026-10-29
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	70	2027-01-01	2026-09-30
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	15	2027-01-01	2026-10-02
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma	Phase 3	Not yet recruiting	Kite, A Gilead Company	600	2027-01-01	2026-10-21
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2026-12-31	2026-11-02
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2026-12-31	2026-10-30
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma	Phase 3	Not yet recruiting	Qilu Pharmaceutical Co., Ltd.	300	2026-12-30	2026-11-12
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM)	Phase 2 / Phase 3	Not yet recruiting	Alliance for Clinical Trials in Oncology	920	2026-12-23	2026-10-22

Paraproteinemias: Clinical Trials

4,280 trials for Paraproteinemias, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding